EXEL News and Press, Exelixis Inc. From 05/09/23

2023-05-09 21:12:07 ET Exelixis, Inc. (EXEL) Q1 2023 Earnings Conference Call May 09, 2023 05:00 PM ET Company Participants Susan Hubbard - EVP, Public Affairs and IR Mike Morrissey - President and CEO Chris Senner - CFO P.J. Haley - EVP, Commercial Dana ...

2023-05-09 16:12:41 ET Exelixis press release ( NASDAQ: EXEL ): Q1 Non-GAAP EPS of $0.16 misses by $0.06 . Revenue of $408.8M (+14.8% Y/Y) misses by $13.86M . Shares -2.5% . GAAP Diluted EPS of $0.12. Collaboration revenues, composed of license reve...

- Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) tod...

2023-05-08 10:28:00 ET Exelixis ( NASDAQ: EXEL ) handed investor Farallon Capital a victory in its proxy fight after board member Lance Willsey informed the board Sunday he would resign immediately and the board said it won't challenge Farallon nominee's David Johnson ...

Pleased that Dave Johnson is Now Anticipated to Join Fellow Farallon Nominees Tom Heyman and Bob Oliver on Exelixis’ Board of Directors Urges Shareholders to Send Clearest Message Possible That the Status Quo Cannot Continue by Voting to Elect All Three of Farallon’s Ind...

Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that Lance Willsey, M.D. has informed the Board of Directors of his decision to resign from the Board, effective immediately. The Board recommends shareholders vote in favor of its remaining 10 director nominees and wil...

– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10 at 1:40 p.m. ET / 10:40 a.m. PT. T...

2023-05-03 14:22:12 ET Exelixis ( NASDAQ: EXEL ) holder Farallon Capital Management filed definitive proxy materials in its battle for board seats with the biotech company. Farallon, which owns ~7.2% stake in Exelixis ( EXEL ), also sent a letter to shareholders on Wedne...

Files Definitive Proxy Materials and Sends Letter to Exelixis Shareholders Encourages Shareholders to Show that the Status Quo Cannot Continue by Voting to Elect All Three of Farallon’s Independent Nominees on the WHITE Proxy Card Visit www.FocusEXEL.com ...

Urges Shareholders to Vote " FOR " All of Exelixis’ 11 Recommended Director Nominees on the GOLD Proxy Card Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that it has filed its definitive proxy materials with the Securities and Exchange Co...